휴마시스
Financials
Valuation Metrics
휴마시스's Market Cap is ₩570B. At end of 2025 it was ₩1251B. Ranked #1613 of 2,410 in KR market (top 67%), #953 of 1,631 on KOSDAQ (top 58%), #61 of 94 in Health Care Equipment & Services (top 65%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 57.00B KRW | KR#1,613/2,410 Sec#61/94 |
| Revenue | 31.73B KRW | KR#2,006/2,410 Sec#63/94 |
| Net Income | -26.63B KRW | KR—/2,410 Sec—/94 |
| Total Assets | 335.01B KRW | KR#977/2,410 Sec#20/94 |
| Net Assets | 238.77B KRW | KR#849/2,410 Sec#21/94 |
| Employees | 69 | KR#1,883/2,410 Sec#76/94 |
| Value | ||
| P/B | 0.24x | KR#249/2,410 Sec#2/94 |
| P/S | 1.80x | KR#1,805/2,410 Sec#51/94 |
| Profitability | ||
| ROE | -11.15% | KR#1,964/2,410 Sec#69/94 |
| ROA | -7.95% | KR#2,047/2,410 Sec#72/94 |
| Op. Margin | -33.75% | KR#2,180/2,410 Sec#75/94 |
| Revenue Growth | -15.36% | KR#2,039/2,410 Sec#85/94 |
| Financial Health | ||
| Debt Ratio | 40.30% | KR#794/2,410 Sec#42/94 |
| Total Debt | 15.47B KRW | KR#1,482/2,410 Sec#44/94 |
| Cash | 63.27B KRW | KR#649/2,410 Sec#10/94 |
| Current Ratio | 2.06x | KR#841/2,410 Sec#48/94 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,410 Sec—/94 |
| Performance | ||
| 1Y Return | -62.22% | KR#2,195/2,410 Sec#85/94 |
| 1M Return | -11.83% | KR#982/2,410 Sec#37/94 |
| From 52W High | -65.65% | KR#1,891/2,410 Sec#71/94 |
| 1Y MDD | -70.95% | KR#1,997/2,410 Sec#74/94 |
| Trading | ||
| Volume | 21,824 shares | KR#816/2,410 Sec#31/94 |
| Trading Value | 50.1M KRW | KR#1,276/2,410 Sec#52/94 |
| Foreign Own. | 0.00% | KR—/2,410 Sec—/94 |
| Per Share | ||
| EPS | -1,079 KRW | KR—/2,410 Sec—/94 |
| BPS | 9,677 KRW | KR#1,018/2,410 Sec#21/94 |
Company Info
Humasis, established in 2000 as a manufacturer of in-vitro diagnostic medical devices, was listed on the KOSDAQ market in 2017 after merging with HI No. 2 Special Purpose Acquisition Company. The company specializes in the development and production of POCT immunoassay reagent product lines. Through its subsidiary, Billionths, Humasis also manufactures condoms and medical rubber products and operates an entertainment business. It is pursuing business diversification by obtaining approval for new objectives like mineral development and sales at its 2024 regular general meeting of shareholders and is headquartered in Anyang-si, Gyeonggi-do.